French set up expert groups on emerging technology:
This article was originally published in Clinica
Executive Summary
The French healthcare products safety agency, AFSSaPS, has set up three expert groups to ensure that it has at its fingertips the necessary responses to problems related to cutting-edge developments in healthcare techniques and materials. The first will assess applications for gene therapy clinical trials, investigate any "undesirable effects" of such investigations and give an opinion on any related questions likely to arise in biomedical research. The second, on cell therapy (excluding haematopoietic stems cells intended for haematopoietic reconstitution) will have a similar brief. The third is a working group on non-clinical aspects of healthcare products, which will review the techniques used in toxicology to define good practice requirements that may eventually be incorporated into new regulations.
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.